The eff ect of fenoldopam and dopexamine on cytokine and endotoxin release following on-pump coronary artery bypass grafting: A prospective randomized double-blind trial

Heart Surgery Forum

Volumn 13, Issue 6, 2010, Pages

  Adluri, Rajeshwara K P ^a   Singh, Arvind V ^a   Skoyles, Julian ^b   Robins, Adrian ^d   Parton, Joan ^e   Baker, Mya ^c   Mitchell, Ian M ^a  

^a Departments of Cardiac Surgery   (United Kingdom)

^b Departments of Cardiac Anaesthesia   (United Kingdom)

^c NOTTINGHAM CITY HOSPITAL   (United Kingdom)

^d QUEEN S MEDICAL CENTRE   (United Kingdom)

^e CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT COMPONENT C3A; COMPLEMENT COMPONENT C4A; COMPLEMENT COMPONENT C5A; CYTOKINE; DOPEXAMINE; ENDOTOXIN; FENOLDOPAM; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; TUMOR NECROSIS FACTOR ALPHA; ANTIINFLAMMATORY AGENT; DOPAMINE; DRUG DERIVATIVE;

ADULT; AGED; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; CYTOKINE RELEASE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG MECHANISM; FEMALE; HEART LEFT VENTRICLE FUNCTION; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; PERIOPERATIVE PERIOD; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; ARTICLE; DRUG COMBINATION; METABOLISM; MIDDLE AGED; MYOCARDITIS; PROSPECTIVE STUDY; TREATMENT OUTCOME;

AGED; ANTI-INFLAMMATORY AGENTS; CORONARY ARTERY BYPASS; CYTOKINES; DOPAMINE; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; ENDOTOXINS; FEMALE; FENOLDOPAM; HUMANS; MALE; MIDDLE AGED; MYOCARDITIS; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 78650602134     PISSN: 10983511     EISSN: 15226662     Source Type: Journal    
DOI: 10.1532/HSF98.20101073     Document Type: Conference Paper

References (25)

1. Adluri RKP, Singh AV, Skoyles J, et al. 2009. The effect of fenoldopam and dopexamine on hepatic blood flow and hepatic function following coronary artery bypass grafting with hypothermic cardiopulmonary bypass. Eur J Cardiothorac Surg 35:988-94.
2. Bach F, Grundmann U, Baeur M, et al. 2002. Modulation of the inflammatory response to cardiopulmonary bypass by dopexamine and epidural anesthesia. Acta Anaesthesiol Scand 46:1227-35.
3. Berendes E, Möllhoff T, Van Aken H, et al. 1997. Effects of dopexamine on creatinine clearance, systemic inflammation, and splanchnic oxygenation in patients undergoing coronary artery bypass grafting. Anesth Analg 84:950-7.
4. Brodgen RN, Markham A. 1997. Fenoldopam: a review of its pharmacodynamic and pharmacokinetic properties and intravenous clinical potential in the management of hypertensive urgencies and emergencies. Drugs 54:634-50.
5. Chenoweth DE, Cooper SW, Hugli TE, Stewart RW, Blackstone EH, Kirklin JW. 1981. Complement activation during cardiopulmonary bypass: evidence for generation of C3a and C5a anaphylatoxins. N Engl J Med 304:497-503.
6. Cremer J, Martin M, Redl H, et al. 1996. Systemic inflammatory response syndrome after cardiac operations. Ann Thorac Surg 61:1714-20.
7. Elgebaly SA, Houser SL, el Kerm AF, Doyle K, Gillies C, Dalecki K. 1994. Evidence of cardiac inflammation after heart operations. Ann Thorac Surg 57:391-6.
8. Gombotz H, Plaza J, Mahla E, Berger J, Metzler H. 1998. DA1-receptor stimulation by fenoldopam in the treatment of post cardiac surgical hypertension. Acta Anaesthesiol Scand 42:834-40.
9. Halpenny M, Laksmi S, O'Donnell A, O'Callaghan-Enright S, Shorten GD. 2001. Fenoldopam: renal and splanchnic effects in patients undergoing coronary artery bypass grafting. Anaesthesia 56:953-60.
10. Jansen NJ, van Oeveren W, Gu YJ, van Vliet MH, Eijsman L, Wildevuur CR. 1992. Endotoxin release and tumor necrosis factor formation during cardiopulmonary bypass. Ann Thorac Surg 54:744-8.
11. Kirklin JK, Westaby S, Blackstone EH, Kirklin JW, Chenoweth DE, Pacifico AD. 1983. Complement and the damaging effects of cardiopulmonary bypass. J Thorac Cardiovasc Surg 86:845-57. (Pubitemid 14209268)
12. Lisbon A. 2003. Dopexamine, dobutamine, and dopamine increase splanchnic blood flow: what is the evidence? Chest 123(suppl):460S-3S.
13. Mathur VS, Swan SK, Lambrecht LJ, et al. 1999. The effects of fenoldopam, a selective dopamine receptor agonist, on systemic and renal hemodynamics in normotensive subjects. Crit Care Med 27:1832-7.
14. Morelli A, Rocco M, Conti G, et al. 2004. Effects of short-term fenoldopam infusion on gastric mucosal blood flow in septic shock. Anesthesiology 101:576-82.
15. Nilsson L, Kulander L, Nyström SO, Eriksson O. 1990. Endotoxins in cardiopulmonary bypass. J Thorac Cardiovasc Surg 100:777-80.
16. Ohri SK, Bjarnason I, Pathi V, et al. 1993. Cardiopulmonary bypass impairs small intestinal transport and increase gut permeability. Ann Thorac Surg 55:1080-6.
17. Riddington DW, Venkatesh B, Boivin CM, et al. 1996. Intestinal permeability, gastric intramucosal pH, and systemic endotoxemia in patients undergoing cardiopulmonary bypass. JAMA 275:1007-12.
18. Rocke DA, Gaffin SL, Wells MT, Keon Y, Brock-Utine JG. 1987. Endotoxemia associated with cardiopulmonary bypass. J Thorac Cardiovasc Surg 93:832-7.
19. Schwarte LA, Picker O, Schindler AW, Fournell A, Scheeren TW. 2003. Fenoldopam - but not dopamine - selectively increases gastric mucosal oxygenation in dogs. Crit Care Med 31:1999-2005.
20. Sharpe DAC, Mitchel IM, Kay EA, McGoldrick JP, Munsch CM, Kay PH. 1999. Enhancing liver blood flow after cardiopulmonary bypass: the effects of dopamine and dopexamine. Perfusion 14:29-36.
21. Tao W, Zwischenberger JB, Nguyen, et al. 1995. Gut mucosal ischemia during normothermic cardiopulmonary bypass results from blood flow redistribution and increased oxygen demand. J Thorac Cardiovasc Surg 110:819-28.
22. Taylor KM, Bain WH, Jones JV, Walker MS. 1976. The effect of hemodilution on plasma levels of cortisol and free cortisol. J Thorac Cardiovasc Surg 72:57-61.
23. Utley JR. 1990. Pathophysiology of cardiopulmonary bypass: current issues. J Card Surg 5:177-89.
24. Wan S, LeClerc JL, Vincent JL. 1997. Inflammatory response to cardiopulmonary bypass: mechanisms involved and possible therapeutic strategies. Chest 112:676-92.
25. Wan S, Marchant A, DeSmet JM, et al. 1996. Human cytokine response to cardiac transplantation and coronary artery bypass grafting. J Thorac Cardiovasc Surg 111:469-77.